Mannosulfan
Chemical compound
- L01AB03 (WHO)
- 1,2,5,6-Tetrakis-O-(methylsulfonyl)-D-mannitol
- 7518-35-6 Y
- 24140
- 16736959
- 135FQ40L36
- Interactive image
- CS(=O)(=O)OC[C@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)C)OS(=O)(=O)C)O)O)OS(=O)(=O)C
InChI
- InChI=1S/C10H22O14S4/c1-25(13,14)21-5-7(23-27(3,17)18)9(11)10(12)8(24-28(4,19)20)6-22-26(2,15)16/h7-12H,5-6H2,1-4H3/t7-,8-,9-,10-/m1/s1
- Key:UUVIQYKKKBJYJT-ZYUZMQFOSA-N
Mannosulfan (INN) is an alkylating agent with the potential for the treatment of cancer. It is not approved by the United States FDA for cancer treatment. Research suggests it is less toxic than the alkyl sulfonate Busulfan.[1]
References
- ^ Jeswani G, Paul SD (2017). "Recent Advances in the Delivery of Chemotherapeutic Agents". Nano- and Microscale Drug Delivery Systems. pp. 281–98. doi:10.1016/B978-0-323-52727-9.00015-7. ISBN 978-0-323-52727-9.
External links
- Media related to Mannosulfan at Wikimedia Commons
- v
- t
- e
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e